Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Limited, a development stage enterprise, covers the period of November 24, 2025. The registrant is headquartered in Melbourne, Australia, and files annual reports under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate governance rather than financial performance data.
Material Changes
No material changes to financial position or operations are reported in this filing. The document serves primarily to disclose a specific corporate event regarding director interests.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. The primary disclosure is the submission of Exhibit 99.1, an "Initial Director's Interest Notice" for an individual named Stamler.
Investor Verification Checklist
- Verify the details of the Director's Interest Notice for Stamler referenced in Exhibit 99.1.
- Confirm the status of the company's active Registration Statements on Form S-8 and Form F-3 into which this report is incorporated.
- Review the most recent Form 20-F for actual financial performance data, as this filing contains none.